Rhythm Pharmaceuticals, Inc. RYTM 深 滬
已收盤 11-06 16:00:00 美东时间
112.28
+7.260
+6.91%
華盛通- 最 高113.285
- 今 開107.10
- 成交量 493.56万股
- 最 低 104.31
- 昨 收 105.02
- 總市值 77.31亿
- 52周最高 122.20
- 市盈率 靜 --
- 換手率 7.17%
- 52周最低 74.50
- 委 比 75.00%
- 總股本 6885.21万
- 歷史最高 122.20
- 量 比 1.15
- 振 幅 8.55%
- 歷史最低 3.04
- 每 手 1
- 風險率 9.68%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 大摩上调AMD目标价至725美元；安进、多邻国绩后获华尔街大行看多
今日重点评级关注：康托·菲茨杰拉德：维持Supernus"超配"评级，目标价从67美元升至87美元；丰业银行：维持Atlas Energy Solutions"跑赢大市"评级，目标价从17美元升至18美元
11-05 14:06
美股牛股 | 业绩股集体大涨！Kyndryl飙升30.1%、多邻国涨26%；Medline升18.4%，宣布10亿美元股票回购计划
美股牛股 | 业绩股集体大涨！Kyndryl飙升30.1%、多邻国涨26%；Medline升18.4%，宣布10亿美元股票回购计划
11-05 13:50
美股大行评级 | 苹果、雅诗兰黛、莱迪思半导体均获大行上调目标价
今日重点评级关注：Rosenblatt：维持SiTime"买入"评级，目标价从750美元升至900美元；花旗：维持Madrigal Pharmaceuticals"买入"评级，目标价从725美元升至760美元
11-04 18:17
财报速睇 | Rhythm Pharmaceuticals, Inc. 2026财年Q3营收0.92亿美元，同比增长79.6%；归母净利润亏损0.42亿美元，同比亏损缩窄22.0%
华盛资讯11月4日讯，Rhythm Pharmaceuticals, Inc.公布2026财年Q3业绩，公司Q3营收0.92亿美元，同比增长79.6%，归母净利润亏损0.42亿美元，同比亏损缩窄22.0%。
11-04 08:31
Needham Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $114
Needham analyst Joseph Stringer maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target from $130 to $114.
11-04 03:54
财报速睇 | Rhythm Pharmaceuticals, Inc. 2026财年Q3营收0.92亿美元，同比增长79.6%；归母净利润亏损0.42亿美元，同比亏损缩窄22.0%
华盛资讯11月3日讯，Rhythm Pharmaceuticals, Inc.公布2026财年Q3业绩，公司Q3营收0.92亿美元，同比增长79.6%，归母净利润亏损0.42亿美元，同比亏损缩窄22.0%。
11-03 22:38
William Blair Initiates Coverage On Rhythm Pharmaceuticals with Outperform Rating
William Blair analyst Alethia Young initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform rating.
10-16 22:36
JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Lowers Price Target to $145
JP Morgan analyst Priyanka Grover maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and lowers the price target from $146 to $145.
10-16 00:01
美股大行评级 | 潜在涨幅179.23%！奥本海默上调Aurora Innovation目标价至16美元，维持"跑赢大市"评级
今日重点评级关注：奥本海默：维持Aurora Innovation"跑赢大市"评级，目标价从15美元升至16美元；富国银行：维持Applied Digital"超配"评级，目标价从50美元升至55美元
10-09 16:25
Here’s How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years
Rhythm Pharmaceuticals (NASDAQ:RYTM) has outperformed the market over the past 5 years by 38.46% on an annualized basis producing an average annual return of 50.82%. Currently, Rhythm Pharmaceuticals has a market capitalization of $6.09 billion. Buying $100 In RYTM: If an investor had bought $100 of...
10-08 22:45
